
Opinion|Videos|October 21, 2024
Treatment Flexibility While on Abrocitinib in Atopic Dermatitis (JADE REGIMEN)
Key Takeaways
- Oral JAK inhibitors provide a convenient alternative to injectable biologics, potentially enhancing patient adherence in maintenance therapy.
- These inhibitors target specific inflammatory pathways, offering a tailored approach to managing autoimmune conditions.
Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please discuss data with oral JAK inhibitors as maintenance and rescue treatments.
Advertisement
Related to this article

For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.

Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.

The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.

Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.

Participants described how payer requirements and documentation of steroid exposure shape biologic access.

In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.

Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
Kidney Compass: ORIGIN 3 Final eGFR Data for Atacicept in IgA Nephropathy
4
FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE
5

